LifeSci Capital initiated coverage of Upstream Bio (UPB) with an Outperform rating and $43 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
- 3 Best Stocks to Buy Now, 11/26/2025, According to Top Analysts
- Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements
- Upstream Bio initiated with an Outperform at Evercore ISI
- Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets
- 3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts